SPECT/CT Imaging for Dosimetry in 177Lu-PSMA-617 (Pluvicto) Therapy
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexMale
Age18+
SponsorUniversity of Michigan Rogel Cancer Center
About this trial
This study is being performed to establish the association between absorbed dose to tumor and response and absorbed dose to normal organs and toxicity following Lu177-PSMA radioligand therapy
Eligibility criteria
Qualifiers
* 177Lu-617 PSMA treatment scheduled for mCRPC
Clinically stable as determined by the nuclear medicine clinicians
Male
≥ 18 years of age
Disqualifiers
Patients who are unable to lie flat on the imaging systems long enough to permit imaging protocols to be performed
Trial design
Treatments tested in this trial
- Non-Interventional Study
Treatment groups
60 Participants
are divided into 1 treatment groupSponsors and collaborators
University of Michigan Rogel Cancer Center
Lead sponsor
National Cancer Institute (NCI)
Collaborator
Source ClinicalTrials.gov